CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 129 enrolled
Drug / intervention
ESL 800 mg +1 moredrug
Likely dose
ESL 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06597084
NCT06597084Phase 2Completed
CompareCT.gov

Prevention of Epilepsy in Stroke Patients at High Risk of Developing Unprovoked Seizures: Anti-epileptogenic Effects of Eslicarbazepine Acetate

Bial - Portela C S.A.·interventional·Posted Sep 19, 2024·Updated May 2, 2025

In Brief

A Phase 2 clinical trial evaluating ESL 800 mg and Placebo for Post Stroke Epilepsy. Completed, enrolled 129 participants across 22 sites in 9 countries.

Detailed Summary

This study aims to assess if eslicarbazepine acetate (ESL) treatment (started within 96 hours after stroke occurrence and continued for 30 days) changes the incidence of unprovoked seizures (USs) within the first 6 months after randomisation as compared to placebo

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost Stroke Epilepsy
CountriesAustria, France, Germany, Israel, Italy, Portugal, Spain, Sweden, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 19, 2024
Enrollment StartMay 29, 2019
Primary CompletionSep 11, 2023
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 1.8 years ago

Interventions

ESL 800 mgdrug

800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.

Placebodrug

Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.